Conclusions The combination of PF-8600 and uuto had a tolerable safety profile and demonstrated clinical benefit, including in an NSCLC patient who had progressed on anti-PD1 therapy and achieved a durable partial response. Further combinations with one or both of these immune costimulatory receptor agonist antibodies might enhance their efficacy.

Acknowledgements This study was funded by Pfizer Inc. Editorial support was provided by Chu Kong Liew, PhD, of Engage Scientific Solutions and was funded by Pfizer Inc.

Trial Registration ClinicalTrials.gov: NCT02315066

Ethics Approval The study was approved by the institutional review board at each study center and conducted in accordance with the ethical principles of the Declaration of Helsinki.

Abstracts

P862 CLINICAL BENEFIT POTENTIALLY EVIDENT WITH IMMUNOPHARMACODYNAMIC RESPONSES IN PRIOR-CHECKPOINT FAILED METASTATIC MELANOMA PATIENTS TREATED WITH IMPRIME PGG AND PEMBROLIZUMAB

1Anissa Chan, 1Nandita Bose, 1Nadine Ottoson, 1Xiaohong Qiu, 1Ben Harrison, 1Richard Walsh, 1Paulette Matton, 1Michela Gargano, 1Joanna Cox, 2Michael Chisamore, 1Mark Uhlik, 1Jeremy Graf, 1Biothera Pharmaceuticals, Eagan, MN, USA; 3Merck and Co., Inc., Rahway, NJ, USA

Background Checkpoint inhibitor (CPI) monotherapy has revolutionized the treatment of melanoma, yet most patients are primary nonresponders or develop secondary resistance. Lack of antigen-specific T cell priming and/or immunosuppressive mechanisms leading to T cell exhaustion are critical cancer-extrinsic factors contributing to CPI resistance mechanisms. Immunotherapeutic agents capable of sparking de novo antitumor T cell responses or reinvigorating pre-existing exhausted T cell immunity could help reinitiate the activity of CPI.

Methods Our Phase 2, multi-center, open label study, NCT02981303 in collaboration with Merck & Co., Inc., is evaluating Imprime PGG (Imprime), a novel yeast derived, Dectin-1 agonist, β-glucan PAMP in combination with pembrolizumab (KEYTRUDA®, pembrol) in heavily CPI-pretreated melanoma patients (20 patients; 65%) had >2 prior CPI regimens with 17/20 having previously progressed on pembrol). Patients received Imprime (4 mg/kg) + pembrol (200 mg) intravenously in a 3-week cycle. Here, we present the immunopharmacodynamic (IPD) responses elicited by Imprime and pembrol in the peripheral blood of 19 patients.

Results In the intent-to-treat population (ITT; N=20), the disease control rate was 45% (1 CR and 8 SD), 6-month and 12-month OS rates were 65% and 45% respectively, and median OS (mOS) was 8.8 months. In the patients showing disease control, a significant increase in CH50, the classical pathway complement function (~0.7-2.6-fold), HLA-DR expression on classical monocytes (~0.6-1.94-fold) and reduction of frequency of PD-1+ Tbet-EOMES+ exhausted CD8 T cells (~0.9-4-fold) was observed. Stimulation of peripheral blood mononuclear cells from a subset of patients by CD3/CD28 beads showed enhanced production of IL-2 and IFN-gamma in the CD8 T cells. Some of these IPD responses were also associated with 6-month landmark OS analyses. Additionally, whole blood gene expression analyses showed >2-fold upregulation of several myeloid and T cell activation genes including IFNg, CD83, IP-10, and IL-2RA. Enhanced OS was observed in patients with >1.3 fold increase in CH50 (8/19; HR 0.385; p=0.01) or >1.5-fold reduction in the frequency of exhausted CD8 T cells (8/19; HR 0.102; p=0.001). The IPD responses observed in the ITT population included formation of circulating immune complexes (peak levels ranging from ~4.5-16.1-fold) and production of complement activation protein SC5b9 (~3.4-25.6-fold), and increase in the frequency of HLA-DR+ myeloid cells (~0.43-3.71-fold).

Conclusions Overall, these data, albeit in a small population, demonstrate that Imprime/pembro combination can drive the innate/adaptive IPD responses that are critical for providing clinical benefit to the patients who have progressed through prior CPI treatments.

Ethics Approval The study was approved by central and local ethics committees depending on site requirements. The central IRB for the study is Western Institutional Review Board (WIRB), approval number 20162506; all sites received IRB approval before opening the study at the respective sites.

P863 KEYNOTE-022 PARTS 4 AND 5: PEMBROLIZUMAB PLUS TRAMETINIB FOR PATIENTS WITH SOLID TUMORS OR BRAF WILD-TYPE MELANOMA

1Michele Maio*, 2Matteo Carlo, 3Anthony Joshua, 4Eileen McWhirter, 5Antoni Ribas, 6Paolo Ascierto, 1Wilson Miller, 8Marcus Butler, 4Pier Ferrucci, 6Robert Zielinski, 9Michela Del Vecchio, 11Edward Gasal, 12Razi Ghoor, 12Scott Dieele, 12Elizabeth Croydon, 6Istituto Nazionale Tumori IRCCS Fondazione G. Pascale’, Naples, Italy; 12Lady Davis Institute for Medical Research, Jewish General Hospital, and McGill University, Montreal, QC, Canada; 11MediGenius Institute of Oncology – IRCCS, Milan, Italy; 8Buffalo Medical Group, Williamsville, NY, USA; 10Fondazione IRCCS Istituto Nazionale, Milan, Italy; 12Novartis, East Hanover, NJ, USA; 9Buffalo Medical Group, Williamsville, NY, USA; 12Merck and Co., Inc., Kenilworth, NJ, USA; 9The Angeles Clinic and Research Institute, Los Angeles, CA, USA

Background Pembrolizumab+dabrafenib+trametinib demonstrated promising antitumor activity and acceptable tolerability in BRAF-mutant melanoma in phase 1/2 KEYNOTE-022 parts 1 and 2 (NCT02130466). Pembrolizumab+dabrafenib+trametinib numerically prolonged PFS and DOR versus placebo+dabrafenib+trametinib but had a higher grade 3-5 TRAE rate in part 3. KEYNOTE-022 parts 4 and 5 evaluated pembrolizumab+trametinib.

Methods In part 4 (open-label, 3+3 dose-finding) patients with advanced solid tumors (irrespective of BRAF status) or unresectable/metastatic BRAF wild-type melanoma received pembrolizumab 200 mg Q3W with trametinib as concurrent (2 or 4 weeks of trametinib run-in [1.5 or 2 mg QD]), then pembrolizumab+trametinib [1.5 or 2 mg QD]) or intermittent dosing (2 weeks of trametinib run-in [1.5 or 2 mg QD]), then pembrolizumab+trametinib [1.5 or 2 mg QD; 1 week off/2 weeks on]). Interim MTDs identified in part 4 were confirmed in part 5 using a modified toxicity probability interval design. The primary objectives were safety, tolerability, and ORR by investigator assessment per RECIST v1.1 of the maximum administered or tolerated dose (MAD/MTD) of
pembrolizumab + trametinib. Safety was analyzed for all patients who received at least 1 dose of study drug; patients treated during the trametinib run-in who discontinued study before receiving pembrolizumab were included; patients who did not complete trametinib run-in or receive at least 66% of planned doses during the 6-week dose-limiting toxicity (DLT) evaluable period were not included for DLT evaluation. AEs were graded per NCI CTCAE v4.

**Results** Of 42 enrolled patients, most were female (61.9%); median age was 55.0 years; 57.1% had received 2 prior lines of therapy. At database cutoff (June 26, 2019), median follow-up was 9.0 months (range, 1.4-25.6 months). Of 38 DLT-evaluable patients, 10 had DLTs (table 1). Dosing regimens were selected for confirmation in part 5 based on safety data. Any-grade TRAEs occurred in 39 (92.9%) patients; grade 3-4 TRAEs occurred in 19 (45.2%), none were grade 5. TRAEs led to discontinuation in 8 (19.0%) patients. Immune-mediated AEs occurred in 12 (28.6%) patients, most commonly severe skin reactions (n=6; 14.3%), pneumonitis (n=3; 7.1%), hypothyroidism (n=2; 4.8%). The MTD of concurrent pembrolizumab + trametinib was pembrolizumab 200 mg Q3W and trametinib 1.5 mg QD starting at week 5. cDL2a: 2 weeks of trametinib 1.5 mg QD run-in, concurrent dosing of pembrolizumab 200 mg Q3W and trametinib 1.5 mg QD starting at week 3. cDL2b: 4 weeks of trametinib 2 mg QD run-in, concurrent dosing of pembrolizumab 200 mg Q3W and trametinib 2 mg QD starting at week 5. iDL1: 2 weeks of trametinib 1.5 mg QD run-in, pembrolizumab 200 mg Q3W dosing starting at week 3 with intermittent 1 week off trametinib, 2 weeks on trametinib 1.5 mg QD. iDL2: 2 weeks of trametinib 2 mg QD run-in, pembrolizumab 200 mg Q3W dosing starting at week 3 with intermittent 1 week off trametinib, 2 weeks on trametinib 2 mg QD. DLT, dose-limiting toxicity; TRAE, treatment-related adverse event; ORR, objective response rate.

**Conclusions** Both concurrent or intermittent pembrolizumab + trametinib dosing were feasible and the combination showed antitumor activity in patients with advanced solid tumors or advanced BRAF wild-type melanoma.

---

**COMBINATION OF FECAL MICROBIOTA TRANSPLANTATION FROM HEALTHY DONORS WITH ANTI-PD1 IMMUNOTHERAPY IN TREATMENT-NAÏVE ADVANCED OR METASTATIC MELANOMA PATIENTS**

1Saman Maleki*, 1John Lenehan, 2Jeremy Burton, 1Michael Silverman, 3Seema Nair Parvathy, 1Mikal El-Hajjar, 3Mithunah Krishnamoorthy. 1Western University, London, Canada; 2Lawson Health Research Institute, London, Canada; 3St. Joseph’s Health Care, London, Canada

**Background** Checkpoint inhibitors have changed the outcomes for patients with advanced melanoma. However, many patients still show primary resistance to single-agent therapy. Recently, the role of the gut microbiome in influencing antitumor immunity has been established. Currently, various methods of modifying the gut microbiome of cancer patients are being explored. We report the initial safety results of the first two patients treated on a phase 1 study combining Fecal Microbiota Transplantation (FMT) with single-agent anti-PD1 in treatment-naïve patients with advanced melanoma.

**Methods** Two healthy donors were selected through our screening process and approximately 100 grams of fresh stool was processed and prepared for FMT as per our standardized protocol. FMT recipients were melanoma patients with unresectable or metastatic disease who were treatment naïve for their advanced disease. Bowel preparation was completed the day prior and FMT was performed using oral administration of approximately 40 capsules. Anti-PD1 was started at least 1 week after FMT to allow for microbiome engraftment. Blood